
 Eliem Therapeutics Inc ELYM announced interim results from its ongoing Period 1 trial of ETX-155 for important depressive problem (MDD) and epilepsy. 
...
FHD-609 is a very first-in-class, really potent and selective protein degrader of BRD9Foghorn’s to start with protein degrader application to...
HALIFAX, Nova Scotia, August 13, 2021--(Enterprise WIRE)--Appili Therapeutics Inc. (TSX:APLI OTCQX: APLIF) (the "Firm" or "Appili"), a biopharmaceutical firm establishing...
-- Very first Sufferers Dosed in Stage 1 Medical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma...
NEW YORK and CLEVELAND, Aug. 10, 2021 (Globe NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-built-in chief in gene...
Key Management Appointments Aid Enterprise Advancement as Guide Trials Transfer Towards DataNEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi...
SAN DIEGO, July 29, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has...
SAN DIEGO, July 28, 2021--(Small business WIRE)--Robbins Geller Rudman & Dowd LLP announces that a course motion lawsuit has been...
San Diego, California--(Newsfile Corp. - July 26, 2021) - The Frequency Therapeutics, Inc. (NASDAQ: FREQ) class motion lawsuit costs Frequency...
San Diego, California--(Newsfile Corp. - July 22, 2021) - The Frequency Therapeutics, Inc. class action lawsuit rates Frequency Therapeutics (NASDAQ:...
BOSTON, July 19, 2021 (World NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a medical stage biopharmaceutical corporation focused on developing...
SAN DIEGO, July 12, 2021--(Business WIRE)--Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been submitted...
MORRISTOWN, N.J.--(Company WIRE)--Melinta Therapeutics, LLC (“Melinta”), a industrial-stage organization giving progressive therapies for acute and lifestyle-threatening sicknesses, announces the appointment...
MORRISTOWN, N.J., June 29, 2021--(Enterprise WIRE)--Melinta Therapeutics, LLC ("Melinta"), a business-phase business delivering ground breaking therapies for acute and existence-threatening...
Completed an initial public offering with net proceeds, including the exercise of the underwriters’ option in full, of approximately $48.4...
WATERTOWN, Mass., May possibly 20, 2021 (Globe NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical corporation groundbreaking a...
Dublin, May 20, 2021 (GLOBE NEWSWIRE) -- The "Global Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight...
-- Hearth chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00...
